Slingshot members are tracking this event:
Solanezumab Phase III Alzheimer's data (EXPEDITION-3) expected year end 2016
Do you think this event is important to the companies below? How will it affect their stock price?
The original study design included co-primary endpoints of cognition and function—measured by ADAS-Cog14 (Alzheimer's Disease Assessment Scale-Cognitive subscale) and ADCS-iADL (Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living), respectively. Emerging scientific evidence supports the idea that cognitive decline precedes and predicts functional decline in Alzheimer's disease, particularly in earlier stages of the disease.1,2,3 Thus, Lilly has decided to amend the EXPEDITION3 trial to include a single primary endpoint of cognition (ADAS-Cog14). Functional outcomes will be measured during the trial in the same manner as previously designed, using both the ADCS-iADL and the FAQ (Functional Assessment Questionnaire). These two functional outcomes will now be considered key secondary endpoints for the EXPEDITION3 study.
Slingshot Insights Explained
Nov 23, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Solanezumab, Alzheimer's, Expedition-3